Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 1;21(5):1690.
doi: 10.3390/ijms21051690.

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Affiliations
Free PMC article
Review

Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review

Masahiro Kamata et al. Int J Mol Sci. .
Free PMC article

Abstract

Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients' quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthritis (psoriatic arthritis) and mental disorders. Furthermore, an association with cardiovascular events is indicated. With the advent of biologics, treatment of psoriasis dramatically changed due to its high efficacy and tolerable safety. A variety of biologic agents are available for the treatment of psoriasis nowadays. However, characteristics such as rapidity of onset, long-term efficacy, safety profile, and effects on comorbidities are different. Better understanding of those characteristic leads to the right choice for individual patients, resulting in higher persistence, longer drug survival, higher patient satisfaction, and minimizing the disease impact of psoriasis. In this paper, we focus on the efficacy and safety profile of biologics in psoriasis patients, including plaque psoriasis and psoriatic arthritis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis.

Keywords: biologics; inteleukin-23; interluekin-17; psoriasis; psoriatic arthritis; tumor necrosis factor-α.

Conflict of interest statement

M.K. received grants for research from Torii Pharmaceutical, Eisai, Maruho, and Novartis Pharma, and honoraria for lectures from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Kirin, Eli Lilly, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, and Janssen Pharmaceutical. Y.T. received grants for research from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Hakko Kirin, Taiho Pharmaceutical, Celgene, and Eli Lilly, and honoraria for lectures from Maruho, LEO Pharma, Eisai, AbbVie, Kyowa Kirin, Eli Lilly, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, and Janssen Pharmaceutical.

Similar articles

See all similar articles

References

    1. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339. - DOI - PubMed
    1. Takeshita J., Grewal S., Langan S.M., Mehta N.N., Ogdie A., Van Voorhees A.S., Gelfand J.M. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 2017;76:377–390. doi: 10.1016/j.jaad.2016.07.064. - DOI - PMC - PubMed
    1. Lynde C.W., Poulin Y., Vender R., Bourcier M., Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J. Am. Acad. Dermatol. 2014;71:141–150. doi: 10.1016/j.jaad.2013.12.036. - DOI - PubMed
    1. Ogawa E., Sato Y., Minagawa A., Okuyama R. Pathogenesis of psoriasis and development of treatment. J. Dermatol. 2018;45:264–272. doi: 10.1111/1346-8138.14139. - DOI - PubMed
    1. Cheuk S., Wiken M., Blomqvist L., Nylen S., Talme T., Stahle M., Eidsmo L. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol. 2014;192:3111–3120. doi: 10.4049/jimmunol.1302313. - DOI - PMC - PubMed
Feedback